RVMD: Revolution Medicines Inc Company Value to Net Income

Revolution Medicines Inc - graphic logo of issuer RVMD

The median P/E of Revolution Medicines (RVMD) reflects the business valuation trend, where -20.00 represents the current metric level. Diversifying research across various oncology drugs minimizes the risks associated with individual test failures. The development of unique inhibitors will ensure monopoly pricing power in the future. Despite a reliance on external financing, the value of the company's scientific developments remains stable regardless of market cycles.

Price to Earnings Ratio: Revolution Medicines (RVMD) for 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for Revolution Medicines Inc (RVMD)

- share price and expert price forecast:
Comprehensive company analysis:Revolution Medicines, Inc. - RVMD
Flagship merchandise of Revolution Medicines, Inc.

Revolution Medicines specializes in developing long-term targeted oncology solutions, which ensures a stable revenue stream due to the chronic nature of these diseases. By analyzing the company's current P/E ratio, an investor assesses the relationship between the business's market value and its annual earnings, allowing them to determine the extent of the asset's overvaluation and identify liquidity risks in a timely manner during share price volatility.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|AAPG (Ascentage) - Company Value to Net Income|P/E Multiple CGON (cgoncology.com)|URGN - Price to Earnings Ratio|BCAX: Price to Earnings Ratio|PSNL - P/E Multiple|Erasca Corp (ERAS) - Price to Earnings Ratio|Delcath - Company Value to Net Income|YMAB (Y-mAbs Therapeutics Inc) - P/E Multiple|Market Cap to Earnings Aura Biosciences, Inc. AURA|P/E Multiple CADL|P/E Multiple Accuray (ARAY)|Price to Earnings Ratio SELLAS Life Sciences Group Inc. SLS|ACTU - Price to Earnings Ratio|CTOR: Price to Earnings Ratio|Company Value to Net Income HURA (TuHURA Biosciences Inc.)|TARA (Protara Therapeutics) - Price to Earnings Ratio|Market Cap to Earnings Fate Therapeutics Corp (FATE)|Price to Earnings Ratio WHWK|Price to Earnings Multiple TCRX (TScan Therapeutics, Inc.)|P/E Multiple CSBR|XBIT - Market Cap to Earnings|CEL-SCI Corporation - Price to Earnings Ratio|Company Value to Net Income OSTX|radiopharmtheranostics.com - P/E Multiple|ARTV: Price to Earnings Ratio|ANL (adlainortye.com) - Price to Earnings Ratio|VERU - Business Payback Period|TPST (Tempest Therapeutics, Inc.) - P/E Multiple|P/E Multiple xiliotx.com|Price to Earnings Ratio Enochian BioSciences (RENB)|Price to Earnings Ratio MURA (Mural Oncology PLC)|Price to Earnings Ratio Kairos Pharma Ltd KAPA|P/E Multiple OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV